01 In Vivo CRISPR Editing Is Moving Toward More Targeted Delivery The need to reach specific tissues and cell types is pushing CRISPR-Cas9 development toward more precise in vivo delivery, as conventional systems still have limited access to organs beyond the liver. The NIH launched its $6 million TARGETED Challenge, with up to $1 million per winning solution, specifically to develop programmable delivery systems and non-viral approaches that can cross the blood-brain barrier. This shift toward tissue-specific delivery can expand the use of CRISPR therapies for neurological, cardiovascular, pulmonary, and other diseases that require editing outside the liver.
02 Non-Viral Delivery Systems Are Expanding Beyond Traditional Viral Vectors The need for flexible delivery of large CRISPR-Cas9 components is increasing interest in lipid nanoparticles, polymeric nanoparticles, extracellular vesicles, and other non-viral platforms. A recent peer-reviewed review found that more than 64% of in vivo CRISPR therapies in its clinical-trial analysis used non-viral delivery systems, with lipid nanoparticles accounting for 55.9%. The expanding use of these platforms can improve payload flexibility and support CRISPR delivery to tissues where viral vectors have limited capacity or targeting capability.
01 Expansion of Gene Therapy Research and Rising Genetic Disorders Increase Demand for CRISPR-Cas9 Technologies Drive Market Expansion of gene therapy research is increasing demand for CRISPR-Cas9 tools, reagents, enzymes, and gene-editing platforms across pharmaceutical and biotechnology research. This demand supports greater development activity as researchers evaluate CRISPR-based approaches for modifying disease-associated genes and developing therapeutic candidates. The outcome is higher demand for CRISPR technology supplies and specialized research services, while suppliers expand editing kits, screening tools, and related laboratory products. A real-world application is Casgevy, the first FDA-approved CRISPR/Cas9 therapy, which uses edited blood stem cells to treat sickle cell disease.The burden of inherited genetic disorders creates continued demand for research into therapies that address disease-causing genetic changes. This need increases research activity around CRISPR-Cas9 as developers investigate gene editing for conditions with limited treatment options and significant unmet needs. The outcome is broader demand for CRISPR research platforms, editing reagents, and supporting laboratory services across pharmaceutical and academic settings. Sickle cell disease and transfusion-dependent beta-thalassemia provide real world applications, with the FDA approving Casgevy for both conditions based on CRISPR/Cas9-edited blood stem cells.
March 2026 Beam Therapeutics expanded its precision gene-editing research portfolio through new R&D investments and collaborations supporting next-generation CRISPR-based therapeutic technologies.
October 2025 Intellia Therapeutics expanded strategic collaborations to accelerate the development of CRISPR-based gene-editing therapies across rare diseases and liver-targeted genetic disorders. The partnerships strengthen research and clinical development capabilities.
August 2025 Editas Medicine expanded its in vivo CRISPR-Cas9 research through new preclinical development programs targeting genetic disorders. The initiative strengthens the company's gene-editing innovation pipeline.
May 2025 CRISPR Therapeutics expanded its gene-editing pipeline by advancing multiple CRISPR-Cas9 programs into later-stage clinical development for oncology, autoimmune disorders, and regenerative medicine applications.